Neomercurocromo and colloidal silver for penile lichen sclerosus

Topical application of Neomercurocromo and subsequently of Colloidal Silver (active drugs) or of placebo (NaCl 0.9%) for the treatment of lichen sclerosus: Comparison of efficacy and of safety

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN27941065

Enrollment

Registered

2017-06-23

Start date

2017-05-16

Completion date

Unknown

Last updated

2018-02-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lichen sclerosus of male genitalia Urological and Genital Diseases Lichen sclerosus of male genitalia

Interventions

Patients will be randomly assigned to one of the two groups using an online randomizer: https://www.randomizer.org/ Intervention group: Participants receive active drugs (Neo-Mercurocromo and Colloid

Eligibility

Sex/Gender

Male

Inclusion criteria

Inclusion criteria: 1. Male 2. Aged 18-70 years 3. Referred with a history of lichen sclerosus (LS) of genitalia

Exclusion criteria

Exclusion criteria: 1. HIV infection 2. Any previous treatment for lichen 3. Any other present or past dermatologic disease of male genitalia 4. Penile or scrotal surgery or peircings

Design outcomes

Primary

Measure	Time frame
Lichen Sclerosus (LS) is measured using the LS specific scale at baseline, 1 and 3 months.	—

Secondary

Measure	Time frame
1. Quality of life is measured using the Dermatology Life Quality Index (DLQI)2 at baseline, 1 and 3 months 2. Patient impression of improvement is measured using the Patient Global Impression of Improvement (PGI-I) scale at baseline, 1 and 3 months	—

Countries

Italy

Contacts

Public ContactGiorgio Cavallini

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026